For drinking-water medication in commercial broiler and swine production, the nonsterile oral powder is prepared by dry-blending Lianqiao Jiedu Powder Veterinary Grade API with dextrose monohydrate and citric acid anhydrous in a 500 L ribbon mixer at 15–20 rpm for 15 min. The API fraction is held at 30–50% w/w, citric acid anhydrous at 2–5% w/w, and colloidal silicon dioxide at 0.5–1.0% w/w as a flow aid and anticaking agent. Prior to blending, the API is passed through a 0.425 mm stainless steel sieve to remove compacted agglomerates formed during storage. The final blend is filled into laminated aluminum foil sachets of 100 g and 500 g at room humidity below 45% RH. Moisture content is controlled below 5.0% by Karl Fischer titration per USP 921. Bulk density is typically maintained between 0.55 g/mL and 0.75 g/mL to ensure consistent dosing from sachets. The terminal product is reconstituted at 0.5–1.0 g/L in drinking water for 5–7 days; water temperatures above 45°C are avoided because tannin-containing polyphenolic fractions may precipitate and clog nipple drinker valves. Microbiological release testing follows USP 61 and USP 62, with absence of Salmonella confirmed per ISO 6579-1:2017. The assay of marker constituents, such as chlorogenic acid and forsythin, is performed by HPLC against the Chinese Veterinary Pharmacopoeia monograph for the registered product. Storage in a dry, dark area below 30°C is specified to limit polyphenol oxidation and hygroscopic caking in sachet stock.

What Constrains Uniformity in Direct-Compression Tableting?

In tablet manufacturing for companion-animal and production-animal oral administration, the dry-extract powder is blended with microcrystalline cellulose grade PH-102 at 30–45% w/w, dibasic calcium phosphate anhydrous at 15–25% w/w, croscarmellose sodium at 2–5% w/w, and magnesium stearate at 0.5–1.0% w/w. The lubricant is added as the final component and blended for only 3–5 min to avoid overlubrication, which can retard disintegration and dissolve poorly in aqueous media. Direct compression is carried out on a rotary tablet press with compression force between 8 kN and 18 kN, turret speed 20–40 rpm, and precompression force 2–4 kN. Tablet hardness is maintained at 5–10 kp; friability is tested per USP 1216 and should not exceed 1.0% after 100 rotations. Disintegration is performed per USP 701 in purified water at 37°C, with a limit of 15 min. Content uniformity is evaluated per USP 905 for tablets containing less than 25 mg or less than 25% active drug relative to total mass. The terminal product is a film-coated tablet packed in PVC/PVDC/Alu blisters; aqueous hydroxypropyl methylcellulose coating at 2–3% w/w weight gain reduces moisture uptake and masks bitter herbal notes. Processing is conducted below 50% RH because the multi-herb extract softens above 65% RH and adheres to press tooling. Published compaction data for Lianqiao Jiedu extract formulations are limited; each batch therefore requires pre-compaction evaluation on a single-station instrument before scale-up to high-speed rotary equipment.

Hard-Gelatin Capsule Fill Mechanics and Moisture Sorption Thresholds

Capsule filling for the veterinary API is performed with a tamping-pin dosator or auger filler depending on fill weight and flow characteristics. The dry-extract powder is granulated with isopropanol and polyvinylpyrrolidone K30 at 2–4% w/w to improve flow; the dried granulate is milled through a 0.8 mm screen. The fill blend comprises API at 45–55% w/w, lactose monohydrate at 35–45% w/w, sodium starch glycolate at 2–4% w/w, and magnesium stearate at 0.5–1.0% w/w. Hard-gelatin capsules size 0 or 1 are used for target fill weights of 300–500 mg; total powder volume is adjusted to the capsule body volume after accounting for tapped density. Capsule shell moisture is controlled at 13–16% w/w; storage below 40% RH may cause shell brittleness and splitting during slitting or printing, while above 65% RH the shell softens and may adhere to filling bushings. Fill weight variation is monitored every 15 min with a target relative standard deviation below 3.0%. Disintegration is tested per USP 701; dissolution is evaluated per USP 711 using 900 mL purified water at 37°C ± 0.5°C and paddle speed 50 rpm. The terminal product is sealed in PVC/PVDC/Alu blisters or HDPE bottles with desiccant canisters. Because the herbal extract contains hygroscopic oligosaccharides, desiccant selection is based on isothermal moisture sorption at 25°C and 60% RH. The capsule route is commonly directed at companion-animal dosing where fixed-dose units improve owner compliance and masking of herbal odor is required.

Preparation of a terminally sterilizable injection from a multi-herb powder requires removal of high-molecular-weight polysaccharides, proteins, and particulate matter before filling. The veterinary API is dispersed in purified water at 90–95°C and held for 60 min under stirring; the extraction is repeated twice and the combined decoctions are concentrated under vacuum at 60–70°C to a density of 1.05–1.10 g/mL. Ethanol precipitation is performed by adding cooled 95% ethanol to reach 60–70% v/v; the mixture is held at 4°C for 12–24 h and then filtered through a 0.45 µm polyethersulfone membrane. The filtrate is further clarified through a 0.22 µm PVDF membrane. pH is adjusted to 6.5–7.5 with tromethamine or phosphate buffer. The solution is filled into 10 mL amber glass ampoules under nitrogen flushing. Terminal sterilization is carried out at 121°C for 15 min if thermal degradation studies demonstrate no unacceptable loss of marker compounds; otherwise aseptic filtration is used. Sterility is tested per USP 71; bacterial endotoxins are tested per USP 85 with a limit justified by the maximum daily dose by species and route. Particulate matter is assessed per USP 788. Raw non-decocted herbal powder is not introduced directly into injection formulations because of endotoxin and insoluble fiber loading. Published veterinary pharmacokinetic data for Lianqiao Jiedu injection remain limited; batch-specific stability at 40°C ± 2°C and 75% RH ± 5% RH should be generated to support the intended shelf life. The terminal product is an intramuscular injection for cattle and swine where authorized by the registration file.

When Lianqiao Jiedu Powder Is Carried on Calcium Carbonate for Bulk Feed Inclusion

Feed premix manufacture requires stepwise geometric dilution to achieve distribution uniformity across a complete feed batch. The API is first bound to calcium carbonate or wheat middlings with an average particle size between 150 µm and 250 µm; the initial dilution ratio is 1:10 w/w, followed by a second 1:10 w/w dilution in a 1,000 L ribbon mixer at 15 rpm for 10–15 min. Final premix API content is typically 10–20% w/w; the inclusion rate in complete feed is 0.1–0.5% w/w for top-dress or mixer application in swine and poultry production. Mix uniformity is verified by riffler sampling with a coefficient of variation below 5.0%. The terminal product is packed in 25 kg multi-wall paper bags with a polyethylene liner. Because the herbal powder contains hygroscopic sugars and polyphenols, storage should be below 60% RH to prevent caking and bridging in hoppers. Compatibility with organic acids should be assessed at pH below 5.0; precipitation of tannin-protein complexes can occur in high-protein feed if the premix is added before extrusion. Compliance follows the registration status of the product as a veterinary medicinal premix or complementary feed; if a veterinary medicinal premix is produced, EU GMP Part II and national medicated-feed rules apply, and Salmonella testing per ISO 6579-1:2017 is mandatory for each batch. The premix route is preferred for weaned piglet and starter poultry applications where feed intake is predictable and drinking-water medication is not feasible.

Granulation Binder Selection for Aqueous Oral Drenches

Granules for oral suspension or direct drench administration are manufactured by wet granulation to reduce dust, improve wetting, and allow suspension in field mixing tanks. The API is blended at 40–60% w/w with lactose monohydrate and microcrystalline cellulose PH-101. Polyvinylpyrrolidone K30 at 2–4% w/w is applied as an isopropanol solution. The wet mass is passed through a 0.8 mm screen and dried in a fluid-bed dryer with inlet air temperature 55–65°C and exhaust temperature 35–45°C; final moisture is held below 3.0%. Dried granules are sieved between 0.5 mm and 1.18 mm. Xanthan gum at 0.2–0.5% w/w is added extragranularly as a suspending agent to delay sedimentation after reconstitution. The terminal product is packed in 100 g or 500 g HDPE jars; reconstitution at 50 g/L in tap water forms a suspension for oral drench administration to piglets or calves. Sedimentation volume and resuspendability are tested after 2 h. Dissolution of the soluble fraction may be tested using a modified USP 711 method, but no harmonized veterinary specification exists. Microbial limits follow USP 61 and 62; water activity should remain below 0.60 aw to limit mold growth in dry granules. Particle attrition during pneumatic conveying is minimized by using dilute-phase conveying velocities below 15 m/s; this reduces fines generation and preserves granule size distribution. The granule form is chosen when dose flexibility and rapid reconstitution in on-farm water tanks are required without the dust exposure associated with fine powder.

Automated oral liquid dosing through proportioner pumps in large poultry and swine barns is prepared with the API dispersed or dissolved in purified water containing 0.1–0.2% w/w sodium benzoate and 0.1% w/w potassium sorbate as preservatives. The pH is adjusted to 5.0–6.0 with citric acid or sodium citrate. The bulk solution is recirculated through a 5 µm polypropylene depth filter and then a 1 µm cartridge filter to remove insoluble fiber that could clog proportioner diaphragms. The terminal product is filled into 1 L and 5 L high-density polyethylene containers with tamper-evident caps. Stock solution dosing is typically set at 1–2% v/v in drinking water; the exact rate depends on the delivered marker compound concentration and the registration label. The solution should be protected from light because chlorogenic acid and related polyphenols undergo photo-oxidation; amber or opaque containers are specified. Accelerated stability is conducted at 40°C ± 2°C and 75% RH ± 5% RH for 6 months per ICH Q1A(R2) adapted to veterinary products. Microbial challenge testing is performed per USP 51 to demonstrate preservative effectiveness. Published data on long-term polyphenol stability in this specific aqueous vehicle are limited; therefore, real-time stability under labeled storage conditions is required to establish shelf life. The solution route is suitable for closed-loop medication systems where accurate dosing by water meter is possible and labor for individual animal handling is limited.